Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel Free CREO Stock Alerts

Creo Medical Group (CREO) Competitors

Creo Medical Group logo
GBX 9.73 -0.67 (-6.44%)
As of 10:49 AM Eastern
Compare

CREO vs. TSTL, EKF, SPEC, IUG, and BVC

Should you buy Creo Medical Group stock or one of its competitors? Creo Medical Group's main competitors and comparable companies include Tristel (TSTL), EKF Diagnostics (EKF), INSPECS Group (SPEC), Intelligent Ultrasound Group (IUG), and BATM Advanced Communications (BVC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment & supplies" industry.

How does Creo Medical Group compare to Tristel?

Creo Medical Group (LON:CREO) and Tristel (LON:TSTL) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings, valuation and media sentiment.

44.1% of Creo Medical Group shares are held by institutional investors. Comparatively, 22.4% of Tristel shares are held by institutional investors. 7.0% of Creo Medical Group shares are held by company insiders. Comparatively, 21.0% of Tristel shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Creo Medical Group had 2 more articles in the media than Tristel. MarketBeat recorded 3 mentions for Creo Medical Group and 1 mentions for Tristel. Creo Medical Group's average media sentiment score of 0.46 beat Tristel's score of 0.00 indicating that Creo Medical Group is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Creo Medical Group
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Tristel
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Creo Medical Group has a net margin of 88.33% compared to Tristel's net margin of 15.88%. Tristel's return on equity of 23.64% beat Creo Medical Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Creo Medical Group88.33% 9.56% -20.09%
Tristel 15.88%23.64%9.89%

Creo Medical Group has a beta of 1.563854, suggesting that its stock price is 56% more volatile than the broader market. Comparatively, Tristel has a beta of 0.344, suggesting that its stock price is 66% less volatile than the broader market.

Tristel has higher revenue and earnings than Creo Medical Group. Creo Medical Group is trading at a lower price-to-earnings ratio than Tristel, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Creo Medical Group£7M6.75-£25.04M£1.009.73
Tristel£49.54M3.96£6.54M£16.2425.11

Summary

Tristel beats Creo Medical Group on 7 of the 13 factors compared between the two stocks.

How does Creo Medical Group compare to EKF Diagnostics?

Creo Medical Group (LON:CREO) and EKF Diagnostics (LON:EKF) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation, risk and media sentiment.

Creo Medical Group has a net margin of 88.33% compared to EKF Diagnostics' net margin of 4.86%. Creo Medical Group's return on equity of 9.56% beat EKF Diagnostics' return on equity.

Company Net Margins Return on Equity Return on Assets
Creo Medical Group88.33% 9.56% -20.09%
EKF Diagnostics 4.86%3.58%5.27%

EKF Diagnostics has higher revenue and earnings than Creo Medical Group. Creo Medical Group is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Creo Medical Group£7M6.75-£25.04M£1.009.73
EKF Diagnostics£51.35M2.07£4.68M£0.4752.73

Creo Medical Group has a beta of 1.563854, indicating that its share price is 56% more volatile than the broader market. Comparatively, EKF Diagnostics has a beta of 0.499, indicating that its share price is 50% less volatile than the broader market.

44.1% of Creo Medical Group shares are held by institutional investors. Comparatively, 22.2% of EKF Diagnostics shares are held by institutional investors. 7.0% of Creo Medical Group shares are held by insiders. Comparatively, 40.2% of EKF Diagnostics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Creo Medical Group currently has a consensus price target of GBX 40, suggesting a potential upside of 311.10%. EKF Diagnostics has a consensus price target of GBX 35, suggesting a potential upside of 41.22%. Given Creo Medical Group's higher possible upside, analysts clearly believe Creo Medical Group is more favorable than EKF Diagnostics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Creo Medical Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
EKF Diagnostics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Creo Medical Group had 2 more articles in the media than EKF Diagnostics. MarketBeat recorded 3 mentions for Creo Medical Group and 1 mentions for EKF Diagnostics. Creo Medical Group's average media sentiment score of 0.46 beat EKF Diagnostics' score of 0.00 indicating that Creo Medical Group is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Creo Medical Group
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
EKF Diagnostics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Creo Medical Group beats EKF Diagnostics on 9 of the 16 factors compared between the two stocks.

How does Creo Medical Group compare to INSPECS Group?

INSPECS Group (LON:SPEC) and Creo Medical Group (LON:CREO) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.

INSPECS Group has a beta of 1.603, suggesting that its share price is 60% more volatile than the broader market. Comparatively, Creo Medical Group has a beta of 1.563854, suggesting that its share price is 56% more volatile than the broader market.

INSPECS Group has higher revenue and earnings than Creo Medical Group. INSPECS Group is trading at a lower price-to-earnings ratio than Creo Medical Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
INSPECS Group£193.23M0.53-£4.11M-£9.40N/A
Creo Medical Group£7M6.75-£25.04M£1.009.73

In the previous week, Creo Medical Group had 3 more articles in the media than INSPECS Group. MarketBeat recorded 3 mentions for Creo Medical Group and 0 mentions for INSPECS Group. Creo Medical Group's average media sentiment score of 0.46 beat INSPECS Group's score of 0.00 indicating that Creo Medical Group is being referred to more favorably in the news media.

Company Overall Sentiment
INSPECS Group Neutral
Creo Medical Group Neutral

Creo Medical Group has a net margin of 88.33% compared to INSPECS Group's net margin of -0.52%. Creo Medical Group's return on equity of 9.56% beat INSPECS Group's return on equity.

Company Net Margins Return on Equity Return on Assets
INSPECS Group-0.52% -1.19% 0.45%
Creo Medical Group 88.33%9.56%-20.09%

0.2% of INSPECS Group shares are held by institutional investors. Comparatively, 44.1% of Creo Medical Group shares are held by institutional investors. 19.6% of INSPECS Group shares are held by insiders. Comparatively, 7.0% of Creo Medical Group shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Creo Medical Group beats INSPECS Group on 8 of the 13 factors compared between the two stocks.

How does Creo Medical Group compare to Intelligent Ultrasound Group?

Intelligent Ultrasound Group (LON:IUG) and Creo Medical Group (LON:CREO) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, media sentiment, earnings, risk and dividends.

75.5% of Intelligent Ultrasound Group shares are owned by institutional investors. Comparatively, 44.1% of Creo Medical Group shares are owned by institutional investors. 12.8% of Intelligent Ultrasound Group shares are owned by insiders. Comparatively, 7.0% of Creo Medical Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Intelligent Ultrasound Group has higher earnings, but lower revenue than Creo Medical Group. Intelligent Ultrasound Group is trading at a lower price-to-earnings ratio than Creo Medical Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intelligent Ultrasound Group£6.57M0.00-£2.27M-£0.68N/A
Creo Medical Group£7M6.75-£25.04M£1.009.73

Intelligent Ultrasound Group has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market. Comparatively, Creo Medical Group has a beta of 1.563854, indicating that its stock price is 56% more volatile than the broader market.

In the previous week, Creo Medical Group had 3 more articles in the media than Intelligent Ultrasound Group. MarketBeat recorded 3 mentions for Creo Medical Group and 0 mentions for Intelligent Ultrasound Group. Creo Medical Group's average media sentiment score of 0.46 beat Intelligent Ultrasound Group's score of 0.00 indicating that Creo Medical Group is being referred to more favorably in the news media.

Company Overall Sentiment
Intelligent Ultrasound Group Neutral
Creo Medical Group Neutral

Creo Medical Group has a net margin of 88.33% compared to Intelligent Ultrasound Group's net margin of -23.11%. Creo Medical Group's return on equity of 9.56% beat Intelligent Ultrasound Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Intelligent Ultrasound Group-23.11% -23.58% -13.51%
Creo Medical Group 88.33%9.56%-20.09%

Summary

Creo Medical Group beats Intelligent Ultrasound Group on 8 of the 12 factors compared between the two stocks.

How does Creo Medical Group compare to BATM Advanced Communications?

BATM Advanced Communications (LON:BVC) and Creo Medical Group (LON:CREO) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.

BATM Advanced Communications has higher revenue and earnings than Creo Medical Group. BATM Advanced Communications is trading at a lower price-to-earnings ratio than Creo Medical Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BATM Advanced Communications£104.57M0.35-£278.26K-£3.94N/A
Creo Medical Group£7M6.75-£25.04M£1.009.73

In the previous week, Creo Medical Group had 2 more articles in the media than BATM Advanced Communications. MarketBeat recorded 3 mentions for Creo Medical Group and 1 mentions for BATM Advanced Communications. Creo Medical Group's average media sentiment score of 0.46 beat BATM Advanced Communications' score of 0.00 indicating that Creo Medical Group is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BATM Advanced Communications
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Creo Medical Group
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Creo Medical Group has a net margin of 88.33% compared to BATM Advanced Communications' net margin of -15.91%. Creo Medical Group's return on equity of 9.56% beat BATM Advanced Communications' return on equity.

Company Net Margins Return on Equity Return on Assets
BATM Advanced Communications-15.91% -25.90% 0.58%
Creo Medical Group 88.33%9.56%-20.09%

14.3% of BATM Advanced Communications shares are owned by institutional investors. Comparatively, 44.1% of Creo Medical Group shares are owned by institutional investors. 31.0% of BATM Advanced Communications shares are owned by insiders. Comparatively, 7.0% of Creo Medical Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

BATM Advanced Communications has a beta of 0.754, suggesting that its share price is 25% less volatile than the broader market. Comparatively, Creo Medical Group has a beta of 1.563854, suggesting that its share price is 56% more volatile than the broader market.

Summary

Creo Medical Group beats BATM Advanced Communications on 9 of the 13 factors compared between the two stocks.

Get Creo Medical Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for CREO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CREO vs. The Competition

Export
MetricCreo Medical GroupHealthcare Equipment & Supplies IndustryHealthcare SectorLON Exchange
Market Cap£47.27M£5.35B£7.14B£2.81B
Dividend YieldN/A1.79%2.52%6.18%
P/E Ratio9.7324.67273.40366.21
Price / Sales6.7568.43656.3889,373.40
Price / Cash2.4332.8679.7527.89
Price / Book0.745.6210.426.43
Net Income-£25.04M£149.51M£3.49B£5.89B
7 Day Performance-19.82%-2.28%-1.99%-0.39%
1 Month Performance-23.98%-4.97%-5.15%11.45%
1 Year Performance-18.24%3.89%10.38%16.63%

Creo Medical Group Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CREO
Creo Medical Group
N/AGBX 9.73
-6.4%		GBX 40
+311.1%		-11.7%£47.27M£7M9.73279
TSTL
Tristel
N/AGBX 395
flat		N/A+13.3%£189.89M£49.54M24.32208
EKF
EKF Diagnostics
1.9837 of 5 stars		GBX 26
+1.2%		GBX 35
+34.6%		-18.0%£110.04M£51.35M55.32356
SPEC
INSPECS Group
N/AGBX 92
-4.2%		N/A+134.5%£100.44M£193.23MN/A1,673
IUG
Intelligent Ultrasound Group
N/AN/AN/AN/A£42.76M£6.57MN/A65

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:CREO) was last updated on 10/1/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Here’s Why Trump Won’t End The Iran War
Trump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...
Banyan Hill Publishing | Sponsoredtc pixel